|
Cambridge Cognition Holdings PLC on Wednesday announced a collaboration for its NeuroVocalix and CANTAB products.
The Cambridge-based brain health assessment software provider said it will collaborate with the University of Oxford, providing it with cognitive assessments for a study on Alzheimer's.
The study is titled the Impact of Semaglutide in Amyloid Positivity, and is funded by Danish pharmaceutical firm Novo Nordisk AS. It is investigating the efficacity of semaglutide, a diabetes medication, against the neuropathphysiology of Alzheimer's disease.
The collaboration will provide Cambridge Cognition will validation data for its voice-based solution NeuroVocalix, which will be used to assess cognitive change in the participants. Its CANTAB solution will also be part of the trial.
Shares in Cambridge Cognition were up 2.7% to 131.50 pence on Wednesday morning.
‘We are delighted to be partnering with the University of Oxford to develop better treatments for Alzheimer's disease. We are particularly pleased to be including our voice solution, NeuroVocalix, as we believe it could help track the earliest cognitive indicators of dementia and this study is an important step as we gather further validation data. We have seen strong early uptake of NeuroVocalix following launch to the academic community last year and more than 20 institutions are using it,’ commented Chief Executive Officer Matthew Stork.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
